Trials / Active Not Recruiting
Active Not RecruitingNCT06645665
A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) in Healthy Adult Aged 18 Years and Above
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate the safety, tolerability, and immunogenicity of 3 dose levels of IN006 in healthy adults aged 18 Years and Above; of a revaccination of IN006 given approximately 12 months after the initial vaccination in older adults (aged ≥60 years).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Bivalent RSV Vaccine (IN006) | Formulation for injection |
| BIOLOGICAL | Placebo | 0.9% sodium chloride (normal saline) injection |
Timeline
- Start date
- 2024-11-11
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2024-10-17
- Last updated
- 2026-04-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06645665. Inclusion in this directory is not an endorsement.